172 related articles for article (PubMed ID: 34906694)
21. APOE and Alzheimer's Disease: Evidence Mounts that Targeting APOE4 may Combat Alzheimer's Pathogenesis.
Uddin MS; Kabir MT; Al Mamun A; Abdel-Daim MM; Barreto GE; Ashraf GM
Mol Neurobiol; 2019 Apr; 56(4):2450-2465. PubMed ID: 30032423
[TBL] [Abstract][Full Text] [Related]
22. The effect of apolipoprotein E (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer's disease.
Leoni V
Clin Chem Lab Med; 2011 Mar; 49(3):375-83. PubMed ID: 21388338
[TBL] [Abstract][Full Text] [Related]
23. Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40). Relevance to Alzheimer's disease.
Aleshkov S; Abraham CR; Zannis VI
Biochemistry; 1997 Aug; 36(34):10571-80. PubMed ID: 9265639
[TBL] [Abstract][Full Text] [Related]
24. Senile dementia associated with amyloid beta protein angiopathy and tau perivascular pathology but not neuritic plaques in patients homozygous for the APOE-epsilon4 allele.
Vidal R; Calero M; Piccardo P; Farlow MR; Unverzagt FW; Méndez E; Jiménez-Huete A; Beavis R; Gallo G; Gomez-Tortosa E; Ghiso J; Hyman BT; Frangione B; Ghetti B
Acta Neuropathol; 2000 Jul; 100(1):1-12. PubMed ID: 10912914
[TBL] [Abstract][Full Text] [Related]
25. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
Navarrete LP; Pérez P; Morales I; Maccioni RB
Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
[TBL] [Abstract][Full Text] [Related]
26. Neurobiology of Alzheimer's disease.
Peskind ER
J Clin Psychiatry; 1996; 57 Suppl 14():5-8. PubMed ID: 9024330
[TBL] [Abstract][Full Text] [Related]
27. Dependence of cerebrospinal fluid Tau protein levels on apolipoprotein E4 allele frequency in patients with Alzheimer's disease.
Golombowski S; Müller-Spahn F; Romig H; Mendla K; Hock C
Neurosci Lett; 1997 Apr; 225(3):213-5. PubMed ID: 9147408
[TBL] [Abstract][Full Text] [Related]
28. Aluminum modifies the properties of Alzheimer's disease PHF tau proteins in vivo and in vitro.
Shin RW; Lee VM; Trojanowski JQ
J Neurosci; 1994 Nov; 14(11 Pt 2):7221-33. PubMed ID: 7525898
[TBL] [Abstract][Full Text] [Related]
29. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases.
Sasaki N; Fukatsu R; Tsuzuki K; Hayashi Y; Yoshida T; Fujii N; Koike T; Wakayama I; Yanagihara R; Garruto R; Amano N; Makita Z
Am J Pathol; 1998 Oct; 153(4):1149-55. PubMed ID: 9777946
[TBL] [Abstract][Full Text] [Related]
30. Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease.
Kawarabayashi T; Shoji M; Younkin LH; Wen-Lang L; Dickson DW; Murakami T; Matsubara E; Abe K; Ashe KH; Younkin SG
J Neurosci; 2004 Apr; 24(15):3801-9. PubMed ID: 15084661
[TBL] [Abstract][Full Text] [Related]
31. Oxidative balance in Alzheimer's disease: relationship to APOE, Braak tangle stage, and the concentrations of soluble and insoluble amyloid-β.
Tayler H; Fraser T; Miners JS; Kehoe PG; Love S
J Alzheimers Dis; 2010; 22(4):1363-73. PubMed ID: 20930272
[TBL] [Abstract][Full Text] [Related]
32. AD Hypotheses and Suggested Clinical Trials.
Mandal PK; Samkaria A; Maroon JC
ACS Chem Neurosci; 2021 Nov; 12(21):3968-3971. PubMed ID: 34662512
[TBL] [Abstract][Full Text] [Related]
33. Metal ions influx is a double edged sword for the pathogenesis of Alzheimer's disease.
Wang P; Wang ZY
Ageing Res Rev; 2017 May; 35():265-290. PubMed ID: 27829171
[TBL] [Abstract][Full Text] [Related]
34. Presence of the apolipoprotein E type epsilon 4 allele is not associated with neurofibrillary pathology or biochemical changes to tau protein.
Mukaetova-Ladinska EB; Harrington CR; Roth M; Wischik CM
Dement Geriatr Cogn Disord; 1997; 8(5):288-95. PubMed ID: 9298630
[TBL] [Abstract][Full Text] [Related]
35. Mouse models of Alzheimer's disease: the long and filamentous road.
Phinney AL; Horne P; Yang J; Janus C; Bergeron C; Westaway D
Neurol Res; 2003 Sep; 25(6):590-600. PubMed ID: 14503012
[TBL] [Abstract][Full Text] [Related]
36. Apolipoprotein E immunoreactivity within neurofibrillary tangles: relationship to Tau and PHF in Alzheimer's disease.
Benzing WC; Mufson EJ
Exp Neurol; 1995 Apr; 132(2):162-71. PubMed ID: 7540552
[TBL] [Abstract][Full Text] [Related]
37. Polygenic hazard score: an enrichment marker for Alzheimer's associated amyloid and tau deposition.
Tan CH; Fan CC; Mormino EC; Sugrue LP; Broce IJ; Hess CP; Dillon WP; Bonham LW; Yokoyama JS; Karch CM; Brewer JB; Rabinovici GD; Miller BL; Schellenberg GD; Kauppi K; Feldman HA; Holland D; McEvoy LK; Hyman BT; Bennett DA; Andreassen OA; Dale AM; Desikan RS;
Acta Neuropathol; 2018 Jan; 135(1):85-93. PubMed ID: 29177679
[TBL] [Abstract][Full Text] [Related]
38. The molecular bases of Alzheimer's disease and other neurodegenerative disorders.
Maccioni RB; Muñoz JP; Barbeito L
Arch Med Res; 2001; 32(5):367-81. PubMed ID: 11578751
[TBL] [Abstract][Full Text] [Related]
39. Involvement of WAVE accumulation in Abeta/APP pathology-dependent tangle modification in Alzheimer's disease.
Takata K; Kitamura Y; Nakata Y; Matsuoka Y; Tomimoto H; Taniguchi T; Shimohama S
Am J Pathol; 2009 Jul; 175(1):17-24. PubMed ID: 19497998
[TBL] [Abstract][Full Text] [Related]
40. Alzheimer's disease. The apolipoprotein E connection.
Utermann G
Curr Biol; 1994 Apr; 4(4):362-5. PubMed ID: 7922348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
